Related Experiment Video
Updated: Jul 6, 2025

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq
Published on: April 19, 2013
Exploring the role of purinergic receptor P2RY1 in type 2 diabetes risk and pathophysiology: Insights from human
Arnaud Dance1, Justine Fernandes1, Bénédicte Toussaint1
1Inserm UMR1283, CNRS UMR8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille University Hospital, Lille, France; Université de Lille, Lille, France.
Objective:
Human functional genomics has proven powerful in discovering drug targets for common metabolic disorders. Through this approach, we investigated the involvement of the purinergic receptor P2RY1 in type 2 diabetes (T2D).
Methods:
P2RY1 was sequenced in 9,266 participants including 4,177 patients with T2D. In vitro analyses were then performed to assess the functional effect of each variant. Expression quantitative trait loci (eQTL) analysis was performed in pancreatic islets from 103 pancreatectomized individuals. The effect of P2RY1 on glucose-stimulated insulin secretion was finally assessed in human pancreatic beta cells (EndoCβH5), and RNA sequencing was performed on these cells.
Results:
Sequencing P2YR1 in 9,266 participants revealed 22 rare variants, seven of which were loss-of-function according to our in vitro analyses. Carriers, except one, exhibited impaired glucose control. Our eQTL analysis of human islets identified P2RY1 variants, in a beta-cell enhancer, linked to increased P2RY1 expression and reduced T2D risk, contrasting with variants located in a silent region associated with decreased P2RY1 expression and increased T2D risk. Additionally, a P2RY1-specific agonist increased insulin secretion upon glucose stimulation, while the antagonist led to decreased insulin secretion. RNA-seq highlighted TXNIP as one of the main transcriptomic markers of insulin secretion triggered by P2RY1 agonist.
Conclusion:
Our findings suggest that P2RY1 inherited or acquired dysfunction increases T2D risk and that P2RY1 activation stimulates insulin secretion. Selective P2RY1 agonists, impermeable to the blood-brain barrier, could serve as potential insulin secretagogues.
Insights
Dysfunctional purinergic receptor P2RY1 increases type 2 diabetes risk. Activating P2RY1 stimulates insulin secretion, suggesting P2RY1 agonists as potential treatments for type 2 diabetes.
Area of Science:
- Genetics
- Metabolic Disorders
- Pharmacology
Background:
- Human functional genomics aids in identifying drug targets for metabolic disorders.
- The purinergic receptor P2RY1's role in type 2 diabetes (T2D) warrants investigation.
Purpose of the Study:
- To investigate the involvement of the purinergic receptor P2RY1 in type 2 diabetes (T2D).
- To assess the potential of P2RY1 agonists as insulin secretagogues.
Main Methods:
- Sequencing of P2RY1 in 9,266 participants (4,177 with T2D).
- In vitro functional analysis of P2RY1 variants.
- Expression quantitative trait loci (eQTL) analysis in human pancreatic islets.
- Assessment of P2RY1's effect on glucose-stimulated insulin secretion in human pancreatic beta cells (EndoCβH5) and RNA sequencing.
Main Results:
- 22 rare P2RY1 variants identified; 7 were loss-of-function.
- Carriers of loss-of-function variants showed impaired glucose control.
- P2RY1 variants in a beta-cell enhancer were linked to increased expression and reduced T2D risk.
- P2RY1 activation stimulated insulin secretion; TXNIP identified as a key transcriptomic marker.
Conclusions:
- Inherited or acquired P2RY1 dysfunction increases T2D risk.
- P2RY1 activation stimulates insulin secretion.
- Selective P2RY1 agonists may serve as potential insulin secretagogues for T2D treatment.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

